Amgen licenses '866 patent from Yeda

By Elaine Rigoli

Tampa, Fla., Sept. 19 - Amgen has entered into an agreement to license rights in U.S. Patent No. 6,217,866 ('866 patent) from Yeda Research and Development Co. Ltd., the commercial arm of the Weizmann Institute of Science.

Earlier this week, Yeda was awarded sole ownership of the '866 patent in an opinion and order issued by the U.S. District Court for the Southern District of New York.

Based in Thousand Oaks, Calif., Amgen discovers, develops and delivers human therapeutics.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.